larotrectinib
Jump to navigation
Jump to search
Indications
- tropomyosin receptor kinase (trk) fusion-positive cancers[1]
* response rate 75%
Mechanism of action
- tropomyosin receptor kinase (trk) inhibitor[1]
More general terms
References
- ↑ 1.0 1.1 1.2 Drilon A, Laetsch TW, Kummar S et al Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378:731-739. February 22, 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29466156 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1714448